- Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
Cancer research (2017-04-02)
Demin Li, Carol Bentley, Amanda Anderson, Sarah Wiblin, Kirstie L S Cleary, Sofia Koustoulidou, Tasneem Hassanali, Jenna Yates, Jenny Greig, Marloes Olde Nordkamp, Iva Trenevska, Nicola Ternette, Benedikt M Kessler, Bart Cornelissen, Mark S Cragg, Alison H Banham
PMID28363997
摘要
The tumor suppressor p53 is widely dysregulated in cancer and represents an attractive target for immunotherapy. Because of its intracellular localization, p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful class of anticancer drugs. However, peptides derived from intracellular antigens are presented on the cell surface in the context of MHC I and can be bound by T-cell receptors (TCR). Here, we report the development of a novel antibody, T1-116C, that acts as a TCR mimic to recognize an HLA-A*0201-presented wild-type p53 T-cell epitope, p53
材料